title: R-DHAP: a good small step, but not the journey's end.
authors.affiliation: Department of Lymphoma and Myeloma, UT MD Anderson Cancer Center, Houston, TX 77030, USA. pmclaugh@mdanderson.org
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab; D016879:Salvage Therapy
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D002945:Cisplatin